Article

Resistance to the KRAS <sup>G12D</sup> Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition

2025-05-13

Abstract excerpt

<h4>ABSTRACT</h4> As many as 90% of human pancreatic ductal adenocarcinoma (PDAC) tumors harbor gain-of-function mutations in the KRAS oncogene. Recently, inhibitors of the most common KRAS mutation, KRAS G12D , have entered the clinical arena. However, early evidence suggests that as monotherapy, KRAS G12D inhibitors such as MRTX1133 at best provide brief periods of disease stabilization. Hence, there is a gr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e02d413d-12eb-544b-b3a1-80cdfe4a5cb2
DOI: 10.1101/2025.05.10.653074

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Resistance to the KRAS <sup>G12D</sup> Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET InhibitionDOI 10.1101/2025.05.10.653074Read

Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition.Semantic proximity Read

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.Semantic proximity Read

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic CancerSemantic proximity Read

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationSemantic proximity Read

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaSemantic proximity Read

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culpritSemantic proximity Read

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity Read

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis.Semantic proximity Read

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant TumorsSemantic proximity Read

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Semantic proximity Read